EC Number | Application | Comment | Organism |
---|---|---|---|
4.4.1.5 | medicine | Glo-I is a molecular target for treatment of Bcr-Abl+ leukemias and, in particular, Abl TKI-resistant quiescent Bcr-Abl+ leukemic cells that have acquired stem-like characteristics in the process of adapting to a hypoxic environment | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
4.4.1.5 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
4.4.1.5 | leukemic stem cell | Bcr-Abl+ leukemic stem cell | Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
4.4.1.5 | methylglyoxal + glutathione | - |
Homo sapiens | (R)-S-lactoylglutathione | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
4.4.1.5 | GLO-I | - |
Homo sapiens |
4.4.1.5 | glyoxalase-I | - |
Homo sapiens |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
4.4.1.5 | glutathione | - |
Homo sapiens |
EC Number | Organism | Comment | Expression |
---|---|---|---|
4.4.1.5 | Homo sapiens | compared with the respective parental cells, hypoxia adapted-Bcr-Abl+ cells have higher levels of protein and higher enzyme activity of glyoxalase-I. High Glo-I expression is sustained in hypoxia adapted-chronic myeloid leukemia cells after 6 months in normoxia | up |